CONFERENCE UPDATE: EULAR 2022
Baricitinib yields favorable outcomes in JIA: the phase 3 JUVE-BASIS trial
Exploring the association of systemic glucocorticoids and incident major adverse cardiovascular events in patients with rheumatoid arthritis based on real-world data
Despite their exceptional anti-inflammatory properties, the use of systemic glucocorticoids (GCs) for the treatment of rheumatoid arthritis (RA) remains controversial due to the potential side effects, particularly their role in elevating patients’ risk of cardiovascular (CV) events. A po
Connecting the dots between Parkinson’s disease and rheumatoid arthritis
Chronic in ammation caused by RA is hypothesized to contribute to the development of PD later in life. Autoimmunity has long been suspected to have a role in the initiation and amplication of brain in ammation via the activation of microglia and monocytes. Genomic analyses have also revealed that PD is pleiotropic with various autoimmune diseases. However, previous investigations have shown con icting results.
- Kang J, et al. Rheumatoid Arthritis and Risk of Parkinson Disease in Korea. JAMA Neurol. 2023:e230932.
The 2022 updated guidelines for RA
Based on inputs from a global task force on recent systematic literaturereviews (SLRs) regarding rheumatoid arthritis (RA), experts from theEuropean Alliance of Associations for Rheumatology (EULAR) updatedrecommendations for the RA management.1 The previous guidelineswere updated in 2019.2 One main
Dupilumab as the first and only drug gains FDA approval for treating EoE
Dupilumab, a monoclonal antibody previously indicated for the treatment of atopic dermatitis and asthma, has been recently approved by the United States (US) Food and Drug Administration (FDA) for treating eosinophilic esophagitis (EoE), a chronic, inflammatory disease in which the build-up of a typ
Strong association between high disease activity in rheumatoid arthritis and venous thromboembolism
Over time, it has become clear that rheumatoid arthritis (RA) patients are at increased risk of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism (PE).1 EULAR President Professor Iain McInnes from The University of